Novo Nordisk's Liver-Fat Data Arrive Just as the Market Demands a Bigger Story

STEP-UP analysis shows 88.5% of Wegovy patients returned to normal liver fat by week 72, but Novo Nordisk shares remain down sharply this year.

Fresh clinical evidence has handed Novo Nordisk a timely narrative boost, even as the Danish drugmaker's shares continue to search for a floor after a bruising stretch. An analysis drawn from the STEP-UP trial, presented at the European diabetes conference EASD, found that Wegovy produced a meaningful effect in adults living with obesity and fatty liver disease. Among a evaluated cohort of 55 participants, 88.5% on doses of 2.4 milligrams and 7.2 milligrams had returned to normal liver-fat levels by week 72.

That result lands at a moment when investors are pressing management to prove the company can open new billion-dollar markets beyond simple weight loss. Questions from analysts at September's capital markets day about future pricing power and looming patent expirations had already weighed heavily on the stock.

A Pipeline Built to Broaden the Label

Alongside the liver findings, Novo Nordisk rolled out data on its lead hope, CagriSema. The candidate curbed food cravings in adults with type-2 diabetes, trimmed harmful abdominal fat and preserved bone density during weight loss. In the phase-3 REIMAGINE 5 study, the combination achieved an estimated average weight reduction of 12.4%, against 9.1% for tirzepatide. The REDEFINE 9 trial showed CagriSema cutting body weight by 21.0%, while the placebo arm delivered barely any effect.

Real-world evidence added another layer. An evaluation of treatment data from 636,525 adults with type-2 diabetes found that raising the Ozempic dose to two milligrams was tied to a 6% lower risk of major cardiovascular events than switching to rival tirzepatide.

If Novo Nordisk can convert these encouraging signals into formal label expansions, a credible bull case opens up. Should Wegovy reliably demonstrate benefit against fatty liver disease in future regulatory reviews, the addressable market widens considerably. CagriSema could add further momentum if the combination therapy outpaces existing monotherapies in late-stage trials — not merely suppressing appetite but also easing organ fat and protecting bone stability. Combined with a broader push into oral therapies, that could keep the company at the front of the metabolic-disease market well past the current decade.

The Price of Staying Ahead

Defending margins in the core business against mounting competition — before key semaglutide patents lapse — has become the single factor investors fixate on. The debate over US rebates and reimbursement models is intensifying, and if rivals such as Eli Lilly capture share with their own incretin products, the Danes will be forced onto the back foot. That makes securing additional indications, including liver disease, all the more critical: only clinically proven extra benefit can justify holding the line on reimbursement prices.

Buying innovation is proving expensive. Roughly a week ago, Novo Nordisk secured worldwide rights outside China to the oral phase-1 candidate HRS-1596 from Hengrui Pharma for as much as USD 2.6 billion. Separately, the company agreed to payments of up to EUR 1.165 billion for the use of the PharmaShell delivery system across as many as five development programs. Such deals show management has recognized the risk — and just how large the financial commitment is to protect its innovative edge.

Setbacks That Cost Time and Money

Clinical data alone guarantee nothing at the launch stage, as the hemophilia A program has demonstrated. US regulators are extending their review of the candidate Denecimig because deficiencies at a manufacturing site must be remedied. The FDA flagged neither efficacy nor safety concerns, but no new decision date has been set. Novo Nordisk said the delay leaves its 2026 financial outlook untouched and still aims for a US sales launch in the first half of 2027, provided approval comes through.

Operational hurdles of this kind burn both time and capital. If similar supply or production bottlenecks emerge for high-volume incretin therapies, market share could slip to competitors. Should US price competition sharpen at the same time, margins come under pressure from two directions. And if Novo Nordisk fails to establish new active ingredients before the first copycat products arrive, the valuation discount on the stock could persist.

Where the Shares Stand

On Monday the stock traded at EUR 33.45, down 24% since the start of the year and 39% below its 52-week high of EUR 54.86. A separate reading put the shares at EUR 33.15, a 25% year-to-date decline. As long as the equity can defend its annual low above EUR 30, the groundwork for a bottoming-out remains in place. Confirmation of CagriSema's potential in upcoming study reports could restore investor confidence; a sustained break below that support, however, would risk extending the downtrend.

Sentiment on the sell side remains cautious. On September 29, Deutsche Bank Research kept its "Sell" rating with a price target of DKK 245 following an analysis of weekly prescription data, according to media reports — a stance that reflects the fierce competition in metabolic therapies, where rival products keep ratcheting up share pressure.

Capital returns offer some counterweight. On September 28, Novo Nordisk reported the repurchase of 1,205,000 B-shares during the prior trading week, part of an ongoing buyback program worth up to DKK 15 billion.

The next concrete catalyst is the planned completion of the Hengrui Pharma licensing agreement in the fourth quarter of 2026. Until then, progress in the labs will decide whether Novo Nordisk can break its market downtrend.